SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+5.87%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$671M
AUM Growth
+$671M
(-4.5%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-11.21%
Top 10 Holdings %
Top 10 Hldgs %
36.87%
Holding
176
New
35
Increased
31
Reduced
45
Closed
50
Top Buys
| 1 |
Biogen
BIIB
|
$20.5M |
| 2 |
CELG
Celgene Corp
CELG
|
$10.4M |
| 3 |
CXRX
Concordia International Corp. Common Stock
CXRX
|
$9.03M |
| 4 |
BCOM
B Communications Ltd
BCOM
|
$6.45M |
| 5 |
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
|
$5.32M |
Top Sells
| 1 |
ENDP
Endo International plc
ENDP
|
$18.8M |
| 2 |
Perrigo
PRGO
|
$16.3M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$13.3M |
| 4 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
$12.5M |
| 5 |
Amgen
AMGN
|
$9.21M |
Sector Composition
| 1 | Healthcare | 77.22% |
| 2 | Technology | 6.01% |
| 3 | Utilities | 2.06% |
| 4 | Industrials | 1.46% |
| 5 | Consumer Discretionary | 1.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $53.7M | 5.26% | 177,100 -15,000 | -8% | -$4.55M |
|
2
Gilead Sciences
GILD
$140B
| $37.5M | 3.67% | 320,000 | – | – |
|
3
Pfizer
PFE
$141B
| $29.3M | 2.87% | 874,013 -150,000 | -15% | -$5.03M |
|
4
AbbVie
ABBV
$372B
| $27.3M | 2.68% | 407,000 | – | – |
|
|
5
Biogen
BIIB
$19.4B
| $24.5M | 2.4% | 60,730 +50,730 | +507% | +$20.5M |
|
6
Merck
MRK
$210B
| $22.8M | 2.23% | 400,000 +25,000 | +7% | +$1.42M |
|
|
CELG
7
DELISTED
Celgene Corp
CELG
| $18.5M | 1.81% | 160,000 +90,000 | +129% | +$10.4M |
|
8
Viatris
VTRS
$12.3B
| $11.9M | 1.16% | 175,000 -97,100 | -36% | -$6.59M |
|
9
Ormat Technologies
ORA
$5.56B
| $11.3M | 1.11% | 80,092 | – | – |
|
|
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.5M | 1.03% | 120,000 +7,545 | +7% | +$663K |
|
|
11
Teva Pharmaceuticals
TEVA
$21.1B
| $10.5M | 1.03% | 177,300 -225,519 | -56% | -$13.3M |
|
12
Bausch Health
BHC
$2.74B
| $10.2M | 1% | 45,750 | – | – |
|
13
Novartis
NVS
$245B
| $9.83M | 0.96% | 100,000 | – | – |
|
|
14
Amgen
AMGN
$155B
| $9.24M | 0.91% | 60,200 -60,000 | -50% | -$9.21M |
|
|
CXRX
15
DELISTED
Concordia International Corp. Common Stock
CXRX
| $9.03M | 0.88% | +100,000 | New | +$9.03M |
|
16
Verint Systems
VRNT
$1.23B
| $8.47M | 0.83% | 139,434 +17,130 | +14% | +$1.04M |
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $8.21M | 0.8% | 60,000 -20,000 | -25% | -$2.74M |
|
18
Check Point Software Technologies
CHKP
$20.7B
| $7.25M | 0.71% | 91,087 +19,160 | +27% | +$1.52M |
|
|
SHPG
19
DELISTED
Shire pic
SHPG
| $6.87M | 0.67% | 134,751 | – | – |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.78M | 0.66% | 140,000 -60,000 | -30% | -$2.9M |
|
21
Bristol-Myers Squibb
BMY
$96B
| $6.65M | 0.65% | 100,000 | – | – |
|
|
ALDR
22
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $6.62M | 0.65% | 125,000 -25,000 | -17% | -$1.32M |
|
23
Vanda Pharmaceuticals
VNDA
$279M
| $6.52M | 0.64% | 513,390 -30,000 | -6% | -$381K |
|
|
BCOM
24
DELISTED
B Communications Ltd
BCOM
| $6.45M | 0.63% | +5,977,000 | New | +$6.45M |
|
25
Amicus Therapeutics
FOLD
$2.34B
| $6.37M | 0.62% | 450,000 | – | – |
|